Company: EUDAW
Filing Date: 2025-12-04
Form Type: 6-K
Source: 0001493152-25-026218
Chunk: 0

Company: EUDA Health Holdings Ltd
Filing Date: 2025-12-04
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number: 001-40678

EUDA Health Holdings Limited

(Exact Name of Registrant as Specified in its Charter)

60 Kaki Bukit Place, #03-01 Eunos Techpark, Singapore 415979

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: +65 6327 1110</div>

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐

EUDA Health Holdings
Limited (“EUDA” or the “Company”) entered into a securities purchase agreement dated as of November 26, 2025
(the “Purchase Agreement”) with an accredited investor (the “Purchaser”) for the purchase of a convertible
warrant (the “Warrant”) for an aggregate purchase price of $100,000 (the “Purchase Price”). The Warrant
is immediately exercisable into 2,000,000 newly-issued ordinary shares, no par value each, of the Company (the “Warrant Shares”)
at an exercise price of $6.00 per share for ninety (90) days from the issuance date, which may be extended by mutual agreement of the parties (the “Cash Exercise Period”).
During the Cash Exercise Period, the Warrant can only be exercised for cash and the Company will have the right to require the Purchaser
to exercise the Warrant up to 10% of the cumulative dollar trading volume during the Measurement Period (the “Forced Exercise”)
if (i) the closing price of the Company’s ordinary shares on Nasdaq is at or above $7.50 for five (5) consecutive trading days
(the “Measurement Period”); and (ii) the cumulative trading dollar volume over the Measurement Period (the “Cumulative
Volume”) is at least $1,500,000. For a period of two (2) weeks following the end of the Cash Exercise Period (the “Repurchase
Period”), the Company will have the